NCT06556810View on ClinicalTrials.gov

IC14 for Treatment of Acute Decompensated Heart Failure

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

January 31, 2026

Conditions
Acute Decompensated Heart Failure
Interventions
DRUG

Atibuclimab (IC14)

Atibuclimab (IC14) is a monoclonal antibody against human cluster of differentiation (CD)14, a key signaling molecule of the innate immune system

Trial Locations (2)

22908

University of Virginia, Charlottesville

23298

Virginia Commonwealth University, Richmond

Sponsors
All Listed Sponsors
collaborator

University of Virginia

OTHER

collaborator

Virginia Commonwealth University

OTHER

lead

Implicit Bioscience

INDUSTRY